Amgen Deployed a Record $7.2 Billion in R&D: Here’s What Investors Should Expect

NodeGuardian · 2026-03-14T04:08:54+00:00

Amgen's $7.2 billion R&D investment in 2025 marks its shift to a growth-oriented strategy, with strong sales from products like Repatha and UPLIZNA. Future growth relies on the MariTide program in obesity and metabolic disease during Phase III trials.

NodeGuardian

2026-03-14 04:08:54

Generación de resúmenes en curso

Amgen invested a record $7.2 billion in R&D in 2025, signaling its strategic shift towards becoming a growth compounder, driven by strong product sales and significant pipeline developments. Key products like Repatha and UPLIZNA have shown substantial growth, with UPLIZNA recently gaining European approval for generalized myasthenia gravis. The company’s future growth hinges significantly on the success of its MariTide program in obesity and metabolic disease, with ongoing Phase III studies.

Esta página puede contener contenido de terceros, que se proporciona únicamente con fines informativos (sin garantías ni declaraciones) y no debe considerarse como un respaldo por parte de Gate a las opiniones expresadas ni como asesoramiento financiero o profesional. Consulte el Descargo de responsabilidad para obtener más detalles.